Clinical observation of EGFR-TKI as a first-line therapy on advanced non-small cell lung cancer

Chinese Journal of Lung Cancer

Volumn 15, Issue 5, 2012, Pages 299-304

  Li, Jianjie ^a   Qu, Lili ^a   Wei, Xing ^b   Gao, Hongjun ^a   Wang, Weixia ^a   Qin, Haifeng ^a   Tang, Chuanhao ^a   Guo, Wanfeng ^a   Wang, Hong ^a   Liu, Xiaoqing ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^b Pediatrics Department   (China)

Author keywords

Epidermal growth factor receptor; Lung neoplasms; Tyrosine kinase inhibitor

Indexed keywords

ERLOTINIB; GEFITINIB;

ADVANCED CANCER; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; DIARRHEA; DRUG EFFICACY; EXON; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; POINT MUTATION; PROGRESSION FREE SURVIVAL; RASH; SEQUENCE ANALYSIS; SKIN DISEASE; STOMATITIS; TREATMENT RESPONSE;

EID: 84922685373     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: 10.3779/j.issn.1009-3419.2012.05.09     Document Type: Article

References (17)

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 2010, 127(12): 2893-2917.
2. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med, 2002, 346(2): 92-98.
3. Mitsudomi T, Kosaka T, Endoh H, et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol, 2005, 23(11): 2513-2520.
4. Cortes-Funes H, Gomez C, Rosell R, et al. Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients. Ann Oncol, 2005, 16(17): 1081-1086.
5. Taron M, Ichinose Y, Rosell R, et al. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survial in gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res, 2005, 11(16): 5878-5885.
6. Zhou C, Wu Y-L, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-smallcell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol, 2011, 12(8): 735-742.
7. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med, 2010, 362(25): 2380-2388.
8. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma. N Engl J Med, 2009, 361(10): 947-957.
9. Rafael Rosell, Enric Carcereny, Radj Gervais, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol, 2012, 13(3): 239-246.
10. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plusdocetaxel in patients with non-small-cell lung cancer harbouringmutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol, 2010, 11(2): 121-128.
11. Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med, 2009, 361(10): 958-967.
12. Carey KD, Garton AJ, Romero MS, et al. Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res, 2006, 66(16): 8163-8171.
13. Jackman DM, Yeap BY, Sequist LV, et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survial in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res, 2006, 12(13): 3908-3914.
14. Lynch TJ, Kim ES, Eaby B, et al. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities:an evolving paradigm in clinical management. Onclogist, 2007, 12(5): 610-621.
15. Reck M, Gutzmer R. Management of the cutaneous side effets of therapeutic epidermal growth factor receptor inhibition. Onkologie, 2010, 33(8-9): 470-479.
16. Massuti B, Morán T, Porta RC, et al. Multicenter prospective trial of customized erlotinib for advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Final results of the Spanish Lung Cancer Group (SLCG) trial. J Clin Oncol, 2009, 27(15s): abstr 8023.
17. Kim ST, Lee J, Kim JH, et al. Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy. Cancer, 2010, 116(12): 3025-3033.